SNTINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Senti Biosciences Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.23+0.00 (+0.84%)
Close on Oct 19, 2026
- Market cap
- $7.06M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
6.4%
2M of 31M shares
Institutional holders
18
18 new, 0 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Gurumurthy Ramamurthy | 6,142,848 | 19.99% | 13D (active) | Mar 10, 2025 |
| Bayer US Holding LLC | 6,142,848 | 17.82% | 13D (active) amendment | Mar 27, 2026 |
| Armistice Capital, LLC | 536,010 | 9.99% | 13G (passive) | Dec 31, 2024 |
| Wilmot B. Harkey | 509,283 | 9.99% | 13G (passive) | Dec 31, 2024 |
| Mohamad H. Makhzoumi | 3,775,615 | 12.10% | 13D (active) amendment | Mar 27, 2026 |
| NEA Partners 15, L.P. | 3,775,615 | 14.50% | 13D (active) amendment | Mar 6, 2025 |
| CPIF II-7 Limited | 25,748,890 | 54.60% | 13D (active) amendment | Sep 3, 2026 |
| Celadon Partners SPV 24 | 25,748,890 | 54.60% | 13D (active) amendment | Apr 27, 2026 |
| Daniel Mack | 2,220,000 | 8.12% | 13G (passive) amendment | Mar 31, 2025 |
| Celadon Partners, LLC | 13,511,322 | 45.00% | 13D (active) amendment | Jan 19, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SNTI | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 888,000 | 2.85% | $976.80K | New | 0.02% |
| Vanguard Capital Management LLC | 537,504 | 1.73% | $591.25K | New | 0.00% |
| Geode Capital Management, LLC | 187,065 | 0.60% | $205.78K | New | 0.00% |
| Citadel Advisors LLC | 107,100 | 0.34% | $117.81K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 91,193 | 0.29% | $100.31K | New | 0.00% |
| Jane Street Group, LLC | 52,530 | 0.17% | $57.78K | New | 0.00% |
| Menlo Ventures Management, L.P. | 35,737 | 0.11% | $39.31K | New | 0.01% |
| Northern Trust Corp | 32,154 | 0.10% | $35.37K | New | 0.00% |
| XTX Topco Ltd | 23,610 | 0.08% | $25.97K | New | 0.00% |
| Virtu Financial LLC | 22,795 | 0.07% | $25 | New | 0.00% |
| UBS Group AG | 14,432 | 0.05% | $15.88K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 7,344 | 0.02% | $8.08K | New | 0.00% |
| Royal Bank of Canada | 4,015 | 0.01% | $4.00K | New | 0.00% |
| BlackRock, Inc. | 4,004 | 0.01% | $4.40K | New | 0.00% |
| Barclays PLC | 768 | 0.00% | $845 | New | 0.00% |
| SBI Securities Co., Ltd. | 334 | 0.00% | $367 | New | 0.00% |
| Morgan Stanley | 169 | 0.00% | $186 | New | 0.00% |
| Caitong International Asset Management Co., Ltd | 1 | 0.00% | $1 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 18 | 2M | 6.4% | 18 / 0 | 0 / 0 | 2M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of SNTI | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 368,878 | 1.18% | $405.77K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 168,626 | 0.54% | $185.49K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 95,866 | 0.31% | $91.23K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 24,798 | 0.08% | $23.60K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 19,991 | 0.06% | $19.02K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 18,801 | 0.06% | $17.89K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -100 | -0.00% | -$110 | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Timothy K. Lu | CEO, Director | 745,261 | 2.39% | Mar 11, 2026 |
| Kanya Rajangam | Pres. & Chief Med. & Dev. Off. | 107,843 | 0.35% | Mar 11, 2026 |
| John Harry Cross III | Chief Financial Officer | – | – | Mar 11, 2025 |
| Bryan Daniel Baum | Director | – | – | Jul 21, 2025 |
| Donald F. Tang | Director | 10,368 | 0.03% | Jun 27, 2025 |
| Edward T. Mathers | Director | – | – | Jun 27, 2025 |
| James J. Collins | Director | 176,130 | 0.57% | Jun 27, 2025 |
| Fran Schulz | Director | – | – | Jun 27, 2025 |
| Brenda Cooperstone | Director | – | – | Jun 27, 2025 |
| Feng Hsiung | Director | – | – | Jun 27, 2025 |
| Partners SPV 24 Celadon | 10% owner | 9,777,000 | 31.39% | Mar 14, 2025 |
| Mohamad Makhzoumi | 10% owner | – | – | Mar 12, 2025 |
| Forest Baskett | 10% owner | – | – | Mar 12, 2025 |
| World Investments B.V. Bayer | 10% owner | – | – | Mar 12, 2025 |
| Anthony A. Florence Jr. | 10% owner | 3,775,615 | 12.12% | Mar 12, 2025 |
| Scott D. Sandell | 10% owner | 442,615 | 1.42% | Mar 12, 2025 |
| US Holding LP Bayer | 10% owner | 2,809,848 | 9.02% | Mar 12, 2025 |
| Healthcare Llc Bayer | 10% owner | – | – | Mar 12, 2025 |
| New Enterprise Associates 15, L.P. | 10% owner | – | – | Mar 12, 2025 |
| Nea 15 Gp, Llc | 10% owner | 4,426,151 | 14.21% | Mar 12, 2025 |
| NEA Partners 15, L.P. | 10% owner | – | – | Mar 12, 2025 |
| Aktiengesellschaft Bayer | 10% owner | – | – | Mar 12, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kanya Rajangam Pres. & Chief Med. & Dev. Off. | Mar 9, 2026 | Tax withholding | −10,757 | – | – | 74,843 |
| Timothy K. Lu CEO, Director | Mar 9, 2026 | Tax withholding | −80,666 | – | – | 639,583 |
| Kanya Rajangam Pres. & Chief Med. & Dev. Off. | Feb 2, 2026 | Tax withholding | −1,384 | – | – | 85,600 |
| Timothy K. Lu CEO, Director | Feb 2, 2026 | Tax withholding | −4,191 | – | – | 720,249 |
| Partners SPV 24 Celadon 10% owner | Mar 10, 2025 | Conversion | +9,777,000 | – | – | 9,777,000 |
| US Holding LP Bayer 10% owner | Mar 10, 2025 | Conversion | +2,222,000 | – | – | 2,809,848 |
| Anthony A. Florence Jr. 10% owner | Mar 10, 2025 | Conversion | +3,333,000 | – | – | 3,775,615 |
| Kanya Rajangam Pres. & Chief Med. & Dev. Off. | Mar 10, 2025 | Conversion | +33,000 | $2.25 | $74.25K | 33,000 |
| Timothy K. Lu CEO and Interim PFO and PAO, Director | Mar 7, 2025 | Award | +642,358 | – | – | 724,440 |
| Kanya Rajangam Pres. & Chief Med. & Dev. Off. | Mar 7, 2025 | Award | +78,363 | – | – | 86,984 |
| Timothy K. Lu CEO, Director | Feb 6, 2025 | Sale | −545 | $4.36 | $2.38K | 82,082 |
| Kanya Rajangam Pres. & Chief Med. & Dev. Off. | Feb 6, 2025 | Sale | −182 | $4.37 | $795 | 8,621 |
| Timothy K. Lu CEO, Director | Feb 4, 2025 | Sale | −3,922 | $4.07 | $15.96K | 82,627 |
| Kanya Rajangam Pres. & Chief Med. & Dev. Off. | Feb 4, 2025 | Sale | −1,297 | $4.07 | $5.28K | 8,803 |
| Kanya Rajangam Chief Medical & Devt. Officer | Feb 1, 2024 | Award | +101,000 | – | – | 101,000 |
| Deborah Knobelman Chief Financial Officer | Feb 1, 2024 | Award | +101,000 | – | – | 131,000 |
| Timothy K. Lu CEO and President, Director | Feb 1, 2024 | Award | +306,000 | – | – | 865,496 |
| Deborah Knobelman Chief Financial Officer | Oct 3, 2022 | Award | +30,000 | – | – | 30,000 |
| Sponsor LLC Dynamics Director, 10% owner | Jun 8, 2022 | Other | −6,465,500 | – | – | 0 |
| Sponsor LLC Dynamics Director, 10% owner | Jun 8, 2022 | Option exercise | +5,750,000 | – | – | 6,465,500 |
| David R. Epstein Director | Jun 8, 2022 | Award | +112,519 | – | – | 123,252 |
| Omid Farokhzad Director | Jun 8, 2022 | Award | +250,000 | $10.00 | $2.50M | 250,000 |
| Omid Farokhzad Director | Jun 8, 2022 | Other | −4,518,097 | – | – | 1,947,403 |
| Omid Farokhzad Director | Jun 8, 2022 | Option exercise | +5,750,000 | – | – | 6,465,500 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| C. Farokhzad Omid Former Affiliate | Dec 2, 2024 | 83,277 | $179.88K | Dec 2, 2024 | Founder shares |